Home > A. Molecular pathology > TFE3

TFE3

MIM.314310 Xp11.22

Monday 1 December 2003

TFE3, a member of the helix-loop-helix family of transcription factors, binds to the mu-E3 motif of the immunoglobulin heavy-chain enhancer and is expressed in many cell types.

Pathology

- TFE3/ASPL gene fusion by t(X;17)(p11;q25) in

- Fusion SFPQ/TFE3 gene in papillary renal cell carcinoma (9393982)

- A distinctive subset of PEComas harbors TFE3 gene fusions (20871214)

  • Perivascular Epithelioid Cell Tumor With SFPQ/PSF-TFE3 Gene Fusion in a Patient With Advanced Neuroblastoma (19606011)

See also

- TFE3 rearrangement

References

- Utilization of a TFE3 Break-apart FISH Assay in a Renal Tumor Consultation Service. Green WM, Yonescu R, Morsberger L, Morris K, Netto GJ, Epstein JI, Illei PB, Allaf M, Ladanyi M, Griffin CA, Argani P. Am J Surg Pathol. 2013 Aug;37(8):1150-1163. PMID: 23715164

- Validation of a TFE3 break-apart FISH assay for Xp11.2 translocation renal cell carcinomas. Mosquera JM, Dal Cin P, Mertz KD, Perner S, Davis IJ, Fisher DE, Rubin MA, Hirsch MS. Diagn Mol Pathol. 2011 Sep;20(3):129-37. PMID: 21817901

- A distinctive subset of PEComas harbors TFE3 gene fusions. Argani P, Aulmann S, Illei PB, Netto GJ, Ro J, Cho HY, Dogan S, Ladanyi M, Martignoni G, Goldblum JR, Weiss SW. Am J Surg Pathol. 2010 Oct;34(10):1395-406. PMID: 20871214

- Perivascular Epithelioid Cell Tumor With SFPQ/PSF-TFE3 Gene Fusion in a Patient With Advanced Neuroblastoma. Tanaka M, Kato K, Gomi K, Matsumoto M, Kudo H, Shinkai M, Ohama Y, Kigasawa H, Tanaka Y. Am J Surg Pathol. 2009 Jul 13. PMID: 19606011

- Tsuda M, Davis IJ, Argani P, Shukla N, McGill GG, Nagai M, Saito T, Lae M, Fisher DE, Ladanyi M. TFE3 fusions activate MET signaling by transcriptional up-regulation, defining another class of tumors as candidates for therapeutic MET inhibition. Cancer Res. 2007 Feb 1;67(3):919-29. PMID: 17283122

- Amin MB, Patel RM, Oliveira P, Cabrera R, Carneiro V, Preto M, Balzer B, Folpe AL. Alveolar soft-part sarcoma of the urinary bladder with urethral recurrence: a unique case with emphasis on differential diagnoses and diagnostic utility of an immunohistochemical panel including TFE3. Am J Surg Pathol. 2006 Oct;30(10):1322-5. PMID: 17001165

- Argani P, Lal P, Hutchinson B, Lui MY, Reuter VE, Ladanyi M. Aberrant nuclear immunoreactivity for TFE3 in neoplasms with TFE3 gene fusions: a sensitive and specific immunohistochemical assay. Am J Surg Pathol. 2003 Jun;27(6):750-61. PMID: 12766578

- Tonk V, Wilson KS, Timmons CF, Schneider NR, Tomlinson GE. Renal cell carcinoma with translocation (X;1). Further evidence for a cytogenetically defined subtype. Cancer Genet Cytogenet. 1995 May;81(1):72-5. PMID: 7773963

- Tomlinson GE, Nisen PD, Timmons CF, Schneider NR. Cytogenetics of a renal cell carcinoma in a 17-month-old child. Evidence for Xp11.2 as a recurring breakpoint. Cancer Genet Cytogenet. 1991 Nov;57(1):11-7. PMID: 1684532

Portfolio

  • TFE3 positivity in pediatric renal cell carcinoma
  • TFE3 positivity in pediatric renal cell carcinoma
  • TFE3 positivity in pediatric renal cell carcinoma